Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 20/20 | 1.00 |
| ▸ | CYBB | P04839 | 3/20 | 1.00 |
| ▸ | NOX1 | Q9Y5S8 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637790 | 1.00 | NOX4 (1.00) | NOX4CYBBNOX1CYP3A4NOX5 | |
| Hydrochloric Acid SCHEMBL29430193 | 0.99 | NOX4 (0.98) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL3615058 | 0.90 | NOX4 (1.00) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL31511711 | 0.90 | NOX4 (1.00) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL16100998 | 0.85 | NOX4 (0.77) | NOX4CYBBNOX1CYP3A4 | |
| SCHEMBL12107202 | 0.85 | NOX4 (0.77) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL1302967 | 0.84 | NOX4 (0.73) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL14931559 | 0.84 | NOX4 (0.73) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL29523207 | 0.84 | NOX4 (0.73) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL14931655 | 0.84 | NOX4 (0.72) | NOX4CYBBNOX1CYP3A4NOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | claimed |
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2025-07-10 | — | — | US | claimed |
| CN-118831163-A | Application of DDX24 in maintaining blood brain barrier steady state | 中山大学附属第五医院 | 2024-10-25 | — | — | CN | claimed |
| US-20240066021-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-29 | — | — | US | claimed |
| WO-2024006796-A2 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | Fulcrum Therapeutics, Inc. (US) | 2024-01-04 | — | — | WO | claimed |
| EP-4277703-A1 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | Children's Hospital Medical Center (US) | 2023-11-22 | — | — | EP | claimed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| US-11814623-B2 | Methods of treating a wound using epigenetic regulation | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-14 | — | — | US | claimed |
| US-20230241029-A1 | METHODS OF REDUCING POST-SURGICAL METASTASIS | HELLSTRAND KRISTOFFER (SE) | 2023-08-03 | — | — | US | claimed |
| US-20230083417-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-16 | — | — | US | claimed |
| US-10564168-B2 | Method for treating male infertility based on NOX5 protein levels in sperm | EL JAMALI AMINA (US) | 2020-02-18 | — | — | US | claimed |
| EP-3479843-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | GenKyoTex Suisse SA (CH) | 2019-05-08 | — | — | EP | claimed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | claimed |
| WO-2015049655-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF PDE5 INHIBITOR-POORLY RESPONSIVE ERECTILE DYSFUNCTION | GENKYOTEX SA (CH) | 2015-04-09 | — | — | WO | claimed |
| EP-2857399-A1 | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction | GenKyoTex SA (CH) | 2015-04-08 | — | — | EP | claimed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | claimed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | claimed |
| US-8389518-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-03-05 | — | — | US | claimed |
| EP-2139477-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-12-12 | — | — | EP | claimed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223560-A1 | NOX4 INHIBITOR COMPOSITIONS AND METHODS FOR REGENERATION OF DYSTROPHIC MUSCLE | NOX4, NOX1, NOX3 | NOX4 1/4885CYBB 4/4885NOX1 2/4885 |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885NOX1 1/4885 |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | NOX1, NOX5, NOX4 | NOX4 3/4885CYBB 6/4885NOX1 1/4885 |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885NOX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.